2-溴-1-[4-甲基-2-(2-吡啶基)-1,3-噻唑-5-基]-1-乙酮 | 423768-43-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-溴-1-[4-甲基-2-(2-吡啶基)-1,3-噻唑-5-基]-1-乙酮
• 中文别名: 2-溴-1-[4-甲基-2-(2-吡嗪)-1,3-噻唑-5-基]-1-乙酮
• 英文名称: 2-bromo-1-(4-methyl-2-(pyrazine-2-yl)thiazol-5-yl)ethanone
• 英文别名: 2-bromo-1-(4-methyl-2-(pyrazin-2-yl)thiazol-5-yl)ethan-1-one；2-Bromo-1-[4-methyl-2-(2-pyrazinyl)-1,3-thiazol-5-yl]-1-ethanone；2-bromo-1-(4-methyl-2-pyrazin-2-yl-1,3-thiazol-5-yl)ethanone
• CAS: 423768-43-8
• 化学式: C₁₀H₈BrN₃OS
• 分子量: 298.163
• InChiKey: PQWKERRFBZJRSD-UHFFFAOYSA-N

物化性质

• 熔点：
  100 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  84
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C,Xi
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39,S45

SDS

Name:	2-Bromo-1-[4-methyl-2-(2-pyrazinyl)-1 3-thiazol-5-yl]-1-ethanone Material Safety Data Sheet
Synonym:
CAS:	423768-43-8

Section 1 - Chemical Product MSDS Name:2-Bromo-1-[4-methyl-2-(2-pyrazinyl)-1 3-thiazol-5-yl]-1-ethanone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
423768-43-8	2-Bromo-1-[4-methyl-2-(2-pyrazinyl)-1,	90+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 423768-43-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H8BrN3OS
Molecular Weight: 298.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, amines.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 423768-43-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-1-[4-methyl-2-(2-pyrazinyl)-1,3-thiazol-5-yl]-1-ethanone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 423768-43-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 423768-43-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 423768-43-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-1-[4-甲基-2-(2-吡啶基)-1,3-噻唑-5-基]-1-乙酮 、 1-(2-chloro-4-hydroxyphenyl)-3-methylthiourea 以 异丙醇 为溶剂， 反应 1.0h， 以64%的产率得到(Z)-3-chloro-4-((3,4'-dimethyl-2'-(pyrazin-2-yl)-[4,5'-bithiazol]-2(3H)-ylidene)amino)phenol
  参考文献：
  名称：

  对嘧啶生物合成酶DHODH的依赖是突变的KRAS驱动的癌症中的合成致死性脆弱性。

  摘要：

  激活KRAS突变是多种肿瘤类型中的主要致癌驱动因素。合成致死筛选以前曾用于鉴定对KRAS突变细胞的生存至关重要的靶标，但事实证明，将其应用于药物发现具有挑战性，这可能部分是由于单层培养物无法建立肿瘤生物学模型所致。在这里，我们报告高通量合成致命筛选的小分子，选择性抑制软琼脂中KRAS突变细胞系生长的结果。化学计量学分析将大多数KRAS选择性化学系列的目标确定为二氢乳清酸脱氢酶（DHODH）。DHODH抑制作用可干扰多种代谢途径。体内临床前研究表明，在胰腺肿瘤异种移植模型中，DHODH抑制作用具有很强的抗肿瘤活性。

  DOI：

  10.1016/j.chembiol.2018.03.005

文献信息

• METHODS OF INHIBITING PRO MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120302573A1

  公开（公告）日：2012-11-29

  This invention relates to methods for preventing, treating or ameliorating an MMP9 and/or MMP13 mediated syndrome, disorder or disease comprising administering to a subject in need thereof an effective amount of a compound listed in the examples section of this specification, or a form, composition or medicament thereof. Disorders treated and/or prevented include rheumatoid arthritis.

  这项发明涉及预防、治疗或改善由MMP9和/或MMP13介导的综合症、紊乱或疾病的方法，包括向需要的受试者施用本说明书示例部分列出的化合物的有效量，或其形式、组合或药物。治疗和/或预防的疾病包括类风湿关节炎。
• BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120129842A1

  公开（公告）日：2012-05-24

  This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R 5 , R 6 , and R 7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  本发明涉及双噻唑I及其治疗和预防用途，其中变量A，R 5 ，R 6 ，和R 7 在说明书中定义。治疗的和/或预防的疾病包括类风湿性关节炎。
• Physiochemical Tuning of Potent<i>Escherichia coli</i>Anti-Adhesives by Microencapsulation and Methylene Homologation
  作者：Dimitri Alvarez Dorta、Thibaut Chalopin、Adeline Sivignon、Jérôme de Ruyck、Tetiana I. Dumych、Rostyslav O. Bilyy、David Deniaud、Nicolas Barnich、Julie Bouckaert、Sébastien G. Gouin

  DOI：10.1002/cmdc.201700061

  日期：2017.6.21

  trapped water molecule, and π-stacking with Tyr48 of FimH, respectively. Consequently, we developed NeoTazMan homologated with a methylene group for low-pH and mannosidase stability with a conserved NH group and bearing various heterocyclic aglycones. Microencapsulation of the lead NeoTazMan in γ-cyclodextrin dramatically improved water solubility without disrupting the affinity for FimH or the anti-adhesive

  噻唑基氨基甘露糖苷（TazMan）是FimH拮抗剂，具有对抗黏附性大肠杆菌（AIEC）促进克罗恩病患者肠道炎症的抗粘附能力。TazMan铅在体外具有很高的效力，但由于低pH稳定性和水溶性，其体内效率有限。我们最近开发了第二代稳定的TazMan，但抗粘连效果却低于第一代。在本文中，我们报道了FimH中的TazMan铅的共晶体结构，揭示了端粒的NH基团和第二噻唑部分与捕获的水分子提供了正的氢键相互作用，并与FimH的Tyr48形成了π堆积。所以，我们开发了与亚甲基同源的NeoTazMan，以降低pH和甘露糖苷酶的稳定性，并具有一个保守的NH基并带有各种杂环糖苷配基。领先的NeoTazMan微囊在γ-环糊精中的微囊化大大改善了水溶性，而不会破坏对FimH的亲和力或对克罗恩病患者分离出的AIEC的抗粘连作用。
• [EN] MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI<br/>[FR] DÉRIVÉS DE MANNOSE UTILES POUR LE TRAITEMENT DE PATHOLOGIES ASSOCIÉES À E. COLI ADHÉRENTS
  申请人：ENTEROME

  公开号：WO2017021549A1

  公开（公告）日：2017-02-09

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO-(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X' represents OH or X and X' taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6 )-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO-(C1-C6 )-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式(I)的甘露糖衍生物：其中R1代表H、CO-(C1-C6)-烷基或CO-烷基芳基，Y代表单键、CH2、O、NR3、S，A代表O、NH或S，X代表H，X'代表OH或X和X'与它们相连的碳原子形成CO基团，R2代表H、线性或支链(C1-C6)-烷基或CF3，R3代表H、C1-C6烷基、CO-(C1-C6)-烷基、CF3或COCF3，R如权利要求1中所述。式(I)的甘露糖衍生物对治疗与粘附性大肠埃希菌（AEC）存在相关的病理病变有用，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；尿路感染，特别是疼痛性膀胱综合征和膀胱炎，更特别是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症性疾病；以及结直肠癌，特别是结肠癌。
• Mannose derivatives useful for treating pathologies associated with adherent E. coli
  申请人：ENTEROME

  公开号：US10543223B2

  公开（公告）日：2020-01-28

  The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X′ represents OH or X and X′ taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1. The mannose derivatives of formulae (I) are useful for treating pathologies associated with the presence of adherent Escherichia coli (AEC), in particular inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; a urinary tract infection, in particular painful bladder syndrome and cystitis, more particularly interstitial cystitis; irritable bowel syndrome; metabolic diseases such as metabolic obesity, diabetes, hypercholesterolemia; autoimmune inflammatory diseases; and colorectal cancer, in particular colon cancer.

  本发明涉及式 (I) 的甘露糖衍生物： 其中 R1 代表 H、CO-(C1-C6)-烷基或 CO-烷基芳基、 Y 代表单键、CH2、O、NR3、S、 A 代表 O、NH 或 S、 X 代表 H 和 X′ 代表 OH 或 X 和 X′ 与含有它们的碳原子一起构成 CO 基团、 R2 代表 H、直链或支链（C1-C6）-烷基或 CF3、 R3 代表 H、C1-C6 烷基、CO-(C1-C6)-烷基、CF3 或 COCF3，以及 R 如权利要求 1 所述。 式（I）的甘露糖衍生物可用于治疗与粘附性大肠杆菌（AEC）的存在有关的病症，特别是炎症性肠病（IBD），如克罗恩病和溃疡性结肠炎；泌尿道感染，特别是膀胱疼痛综合征和膀胱炎，尤其是间质性膀胱炎；肠易激综合征；代谢性疾病，如代谢性肥胖、糖尿病、高胆固醇血症；自身免疫性炎症；以及结肠直肠癌，特别是结肠癌。